Shares of biotech company Oncothyreon (NASDAQ:ONTY) fell more than 50% yesterday. The company released Phase 3 data for its drug Stimuvax, an experimental vaccine that treats non-small cell lung cancer, which showed that the drug failed to improve overall survival for patients in the clinical trial. In this video, Motley Fool health-care analysts Max Macaluso and Brenton Flynn take us through the details.

Brenton Flynn has no positions in the stocks mentioned above. Max Macaluso, Ph.D. has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.